Browse Category

NASDAQ:ILMN 22 June 2025 - 5 May 2026

For live price, interactive charts, financials and the latest market data, visit Google Finance.
Illumina Stock Rockets 20%+ After Blowout Quarter – What’s Next for ILMN?
Illumina Stock Rockets 20%+ After Blowout Quarter – What’s Next for ILMN?

Illumina Stock Rockets 20%+ After Blowout Quarter – What’s Next for ILMN?

Illumina’s stock has whipsawed in late 2025. After drifting near its 52-week lows, it ticked up to the mid-$90s by mid-October 2025. Following the Oct. 30 earnings report, ILMN exploded higher: by Oct. 31 it was trading around $120 ts2.tech Marketbeat. TS2.tech notes that the stock was “around the high $110s–$120 range” on Oct. 31, a sharp jump from the mid-$90s “just days prior” ts2.tech. The surge was driven by the earnings beat and raised guidance. In one week ILMN recovered roughly 20–25% of its value ts2.tech ts2.tech. Despite the rally, the stock still trades below its Nov 2024 peak and its YTD performance is mixed. Daily trading volume and volatility have spiked as analysts and investors react to the news.
1 November 2025
···
Illumina Stock Surges on Genomics Breakthroughs – What’s Next for ILMN?

Illumina Stock Surges on Genomics Breakthroughs – What’s Next for ILMN?

Illumina’s latest quarterly report provided a much-needed spark for investors. The San Diego-based genomics giant reported $1.084 billion in revenue for Q3, slightly above Wall Street estimates and flat versus the same quarter last yearinvesting.com. While flat growth might not sound impressive, it exceeded Illumina’s own guidance range, marking an improvement in a year where demand had been soft. Adjusted earnings were $1.34 per share, handily beating the ~$1.17 consensusinvesting.com. CEO Jacob Thaysen noted the team “delivered Q3 results that exceeded the high-end of our guidance… driven by revenue acceleration in clinical, our largest market segment.”investing.com Clinical demand picked up nicely, helping offset weaker research academia sales.
31 October 2025
··
Biotech Breakthrough: GRAIL (GRAL) Stock Surges on New Cancer-Detection Data

Biotech Breakthrough: GRAIL (GRAL) Stock Surges on New Cancer-Detection Data

Analysis: GRAIL’s stock performance reflects a wave of optimism about its Galleri cancer-screening test and pending trial results. In late September it broke out to new highs, aided by momentum and positive chatter. The company itself is pushing the narrative: GRAIL President Dr. Josh Ofman proclaims Galleri’s data will usher in a “transformative era for cancer screening,” detecting cancers earlier “when they can be easier to treat and are potentially curable” grail.com.
3 October 2025
···
Top 100 Global Biotechnology Companies Revolutionizing Science and Health

Top 100 Global Biotechnology Companies Revolutionizing Science and Health

Biotechnology is at the forefront of scientific innovation in 2025, driven by companies around the world that are transforming healthcare, agriculture, and industry. This report profiles 100 of the most important global biotechnology companies selected for their global impact, innovation, revenue, scientific breakthroughs, and sector influence. These companies span biopharmaceutical giants, genomics and diagnostics pioneers, agricultural and environmental biotech leaders, industrial biotech innovators, and key providers of biotech tools and services. Each entry includes the company’s headquarters country, primary sector, notable contributions or innovations, and a link to its official website. The list encompasses both publicly traded and private firms, reflecting the worldwide landscape of biotech innovation.
22 June 2025
···········
Follow on Google News
Add as preferred source Open in Google News
AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 STRONG BUY

Constellation Energy

NASDAQ: CEG 95 / 100
#2 BUY

AerCap

NYSE: AER 93 / 100
#3 BUY

Walt Disney

NYSE: DIS 92 / 100
#4 ACCUMULATE

AIG

NYSE: AIG 90 / 100
#5 BUY ON PULLBACK

Cheniere Energy

NYSE: LNG 88 / 100
View full portfolio
Editorial model selection. Not personalised advice.